AIM Vaccine, which is accelerating the iteration and upgrade of rabies vaccines, has achieved new results in new product R&D.

AIM Vaccine announced on November 17th that the company's independently developed serum-free iterative rabies vaccine has recently submitted a pre-application for market registration to the National Medical Products Administration.

AIM Vaccine stated that according to the results of the completed Phase III clinical study, which has been unblinded, the company's serum-free iterative rabies vaccine has good safety, immunogenicity and immune persistence, achieving the preset clinical goals.

Leading Industry Innovation and Expected to Be the First Global Debut

According to the announcement, there are two types of rabies vaccines, one with serum and one without serum, but so far no serum-free rabies vaccine has been registered and launched. The mainstream Vero cell rabies vaccine and human diploid cell rabies vaccine sold on the market are both serum-containing rabies vaccines.

AIM Vaccine introduced that the serum-free iterative rabies vaccine is completely different from the currently available Vero cell rabies vaccine and human diploid cell rabies vaccine containing serum, and is an iteratively upgraded product. The residue of animal serum in vaccine products is one of the important factors causing adverse reactions such as allergies in the vaccinated population. The serum-free iterative rabies vaccine developed by the company does not contain animal serum, significantly improving safety and reducing the probability of adverse reactions.

So far, no serum-free rabies vaccine has been approved and launched on the global market, and this product is expected to be the first product to be launched.

At present, AIM Vaccine has completed the construction of a serum-free iterative rabies vaccine workshop that meets international standards and has completed the production of Phase III clinical trial samples on a commercial scale, with the capability to produce this product on a large scale.

Huge Market Space, Rabies Vaccine Giant Actively Promotes Product Upgrade

According to a WHO survey report, rabies remains a significant public health threat in the 21st century, with a fatality rate of nearly 100% once the disease develops. The potential market consumption of rabies vaccines is large, and the market size is expected to increase to 22 billion yuan by 2030, mainly benefiting from the iteration of new processes and the increase in demand for high-end products.

AIM Vaccine's innovative vaccine R&D has always been at the forefront of the industry in recent years. Among them, in the iteration and upgrade of rabies vaccines, the company has formed a clear strategic layout. From the Vero cell freeze-dried human rabies vaccine, to the iterative serum-free rabies vaccine, to the iterative high-efficacy human diploid cell rabies vaccine, and then to the mRNA iterative rabies vaccine, as the world's second-largest rabies vaccine production company, AIM Vaccine has been accelerating the iteration and upgrade of the rabies vaccine series, leading the in-depth technical iteration and upgrade of global rabies vaccines with its leading rabies vaccine R&D and production capabilities.

In terms of market performance, AIM Vaccine's Vero cell freeze-dried human rabies vaccine has achieved a 100% pass rate in the National Institutes for Food and Drug Control's batch release for seventeen consecutive years since its launch, and its market share has always been among the top in recent years. Compared with the future growth curve and the continuously rising market space, the rabies vaccine giant AIM will have ample opportunities in market competition, continuing to lead the golden track.

In addition, according to the analysis of the research report by China International Trust and Investment Corporation (CITIC), there is currently a shortage of supply for many vaccines worldwide, and some regions have a low rate of self-sufficiency, which is beneficial for domestic vaccine companies to avoid domestic competition and achieve overseas exports. Domestic vaccine companies, with the improvement of innovation capabilities, are accelerating the capture of overseas markets. As an industry leader, AIM Vaccine has several blockbuster innovative single-item products such as the serum-free iterative rabies vaccine entering the harvest period, which has also laid a stronger foundation for its vaccine exports.